← All trials
NCT03840135
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 7, 2018
- Primary completion
- Mar 31, 2019
- Completion date
- Mar 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 172
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NPO Petrovax Pharm LLCLead sponsor
- NPO Petrovax Pharm LLCStudy chair
- NPO Petrovax Pharm LLCReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.